Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response

Clinica Chimica Acta

Volumn 417, Issue , 2013, Pages 8-11

  Rodrigues, A C ^a,e   Sobrino, B ^b   Genvigir, F D V ^a   Willrich, M A V ^a   Arazi, S S ^a   Dorea, E L ^a   Bernik, M M S ^a   Bertolami, M ^c   Faludi, A A ^c   Brion, M J ^b,d   Carracedo, A ^b   Hirata, M H ^a   Hirata, R D C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e Institute of Biomedical Sciences   (Brazil)

Author keywords

Association studies; Dyslipidemia; Pharmacogenomics; SNPs; Statins

Indexed keywords

ABC TRANSPORTER G1; APOLIPOPROTEIN B; ATORVASTATIN; CD36 ANTIGEN; GENOMIC DNA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; APOB GENE; ARTICLE; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER G1 GENE; CASE CONTROL STUDY; CD36 GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEPATIC LIPASE GENE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN INDUCED GENE 2; INTERLEUKIN 10 GENE; INTERLEUKIN 1BETA GENE; INTERLEUKIN 6 GENE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PHARMACOGENETICS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ATHEROSCLEROSIS; DYSLIPIDEMIAS; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; TREATMENT OUTCOME;

EID: 84871750175     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.11.028     Document Type: Article

References (25)

1. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
2. Gotto A.M., Brinton E.A. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2003, 43:717-724.
3. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
4. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. J Am Med Assoc 2007, 298:299-308.
5. Pilia G., Chen W.M., Scuteri A., et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet 2006, 2:e132.
6. Pollin T.I., Hsueh W.C., Steinle N.I., Snitker S., Shuldiner A.R., Mitchell B.D. A genome-wide scan of serum lipid levels in the old order Amish. Atherosclerosis 2004, 173:89-96.
7. Breslow JL. Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility. Annu Rev Genet 2000, 34:233-254.
8. Kathiresan S., Manning A.K., Demissie S., et al. A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet 2007, 8:S17.
9. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
10. Benn M., Stene M.C., Nordestgaard B.G., Jensen G.B., Steffensen R., Tybjaerg-Hansen A. Common and rare alleles in apolipoprotein B contribute to plasma levels of low-density lipoprotein cholesterol in the general population. J Clin Endocrinol Metab 2008, 93:1038-1045.
11. Zhu H., Tucker H.M., Grear K.E., et al. A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol. Hum Mol Genet 2007, 16:1765-1772.
12. Rodrigues A.C., Hirata M.H., Hirata R.D. The genetic determinants of atorvastatin response. Curr Opin Mol Ther 2007, 9:545-553.
13. Mangravite L.M., Wilke R.A., Zhang J., Krauss R.M. Pharmacogenomics of statin response. Curr Opin Mol Ther 2008, 10:555-561.
14. Maggo S.D., Kennedy M.A., Clark D.W. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf 2011, 34:1-19.
15. Rodrigues A.C., Perin P.M.S., Purim S.G., et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci 2011, 12:5815-5827.
16. Morcillo-Suarez C., Alegre J., Sangros R., et al. SNP analysis to results (SNPator): a web-based environment oriented to statistical genomics analyses upon SNP data. Bioinformatics 2008, 24:2790-2791.
17. Edwards J.E., Moore R.A. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003, 4:18.
18. Sandhu M.S., Waterworth D.M., Debenham S.L., et al. LDL-cholesterol concentrations: a genome-wide association study. Lancet 2008, 371:483-491.
19. Leprêtre F., Cheyssac C., Amouyel P., Froguel P., Helbecque N. A promoter polymorphism in CD36 is associated with an atherogenic lipid profile in a French general population. Atherosclerosis 2004, 173:375-377.
20. Love-Gregory L., Sherva R., Sun L., et al. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet 2008, 17:1695-1704.
21. Deeb S.S., Peng R. The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000, 41:155-158.
22. Zambon A., Deeb S.S., Hokanson J.E., Brown B.G., Brunzell J.D. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998, 18:1723-1729.
23. Cenarro A., Artieda M., Gonzalvo C., et al. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. Am Heart J 2005, 150:1154-1162.
24. Zambon A., Deeb S.S., Brown B.G., et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001, 103:792-798.
25. Berk-Planken I.I., Hoogerbrugge N., Stolk R.P., Bootsma A.H., Jansen H. Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care 2003, 26:427-432. DALI. Study Group.